Intelligent Bio Solutions Surges Nearly 29% as Drug Screening System Hits 98.2% Accuracy, Completing FDA 510(k) Data Package

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company delivering rapid, non-invasive testing solutions, announced results on September 1, 2026 from its latest Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, achieving 98.2% total accuracy, 94.6% sensitivity, and 100% specificity in detecting the opiate codeine. Shares jumped as much as 28.7% intraday on trading volume nearly 40 times the daily average. With all clinical data now complete, the company has accelerated its filing timeline and expects to submit its FDA 510(k) application in September 2026.

A Meaningful Jump From the Company’s Prior Study

The improvement over Intelligent Bio Solutions’ previous Method Comparison Study, announced in November 2024, is substantial rather than incremental. That earlier study, conducted with 135 healthy donors, produced 82.2% sensitivity, 100% specificity, and 94.1% accuracy. The new study, conducted across three independent U.S. clinical sites in pre-employment and workplace settings, tested 214 samples (144 true negatives, 70 true positives, 4 false negatives, and zero false positives) against a validated LC-MS/MS laboratory reference method, the accepted gold standard for confirming drug test results. Sensitivity climbed more than 12 percentage points, from 82.2% to 94.6%, while specificity held at a perfect 100% across both studies—meaning the system produced zero false positives in either dataset. That combination of rising sensitivity without sacrificing specificity is precisely the profile the FDA weighs most heavily in a 510(k) submission for a screening device.

Why a Fingerprint-Based Test Matters in the Drug Screening Market

The Intelligent Fingerprinting Drug Screening System detects drug use through sweat collected from a fingerprint rather than urine, saliva, or blood, eliminating the need for direct sample collection under observation. That distinction carries real commercial weight in workplace and pre-employment testing, where observed collection procedures are often the most logistically burdensome and privacy-sensitive part of the process. The system is designed to deliver results in minutes rather than requiring samples to be sent to an external laboratory. INBS has already commercialized the platform internationally, selling into 35 countries and territories through more than 480 active customer accounts, but the product cannot be marketed for drug testing purposes in the United States until it clears FDA 510(k) review. The U.S. represents by far the largest workplace drug testing market globally, making 510(k) clearance the single most consequential near-term catalyst for the company’s growth trajectory.

A Same-Day Financing Round Funds the Next Phase

Intelligent Bio Solutions paired today’s clinical results with a separate announcement of a private placement of up to $15 million to a single existing institutional investor, priced at-the-market under Nasdaq rules. Raising capital from an existing rather than a new institutional holder often signals continued confidence from an investor already familiar with the company’s progress, and the at-the-market pricing structure limits dilution relative to a discounted placement. The timing is unlikely to be coincidental: completing the FDA data package and securing fresh capital on the same day gives the company both the clinical package and the balance sheet needed to fund the 510(k) submission process and prepare for a potential U.S. commercial launch pending clearance. Investors should note that FDA review timelines for 510(k) submissions typically run several months from acceptance, meaning clearance itself, not just submission, remains the next material catalyst to watch.

Strategic Investment Summary

• Study Results: Intelligent Bio Solutions (NASDAQ: INBS) reported 98.2% total accuracy, 94.6% sensitivity, and 100% specificity for its Drug Screening System detecting codeine, across 214 samples at three independent U.S. clinical sites, sending shares up as much as 28.7% intraday on 39.9x average volume.
• Improvement Over Prior Study: Sensitivity rose from 82.2% in the November 2024 study to 94.6% in the new study, while specificity held at a perfect 100% in both, with zero false positives recorded across either dataset.
• FDA Submission Accelerated: With all 510(k) clinical data now complete, INBS expects to submit its FDA application in September 2026, positioning for a planned U.S. market entry pending clearance.
• Existing Commercial Base: The Intelligent Fingerprinting Drug Screening System is already sold in 35 countries and territories through more than 480 active customer accounts, giving the company an established international base ahead of a potential U.S. launch.
• Same-Day Financing: INBS separately announced a private placement of up to $15 million to a single existing institutional investor, priced at-the-market under Nasdaq rules, funding the submission process and launch preparation.
• Next Catalyst: FDA 510(k) review timelines typically run several months from acceptance; actual clearance, rather than submission alone, remains the key event investors should watch for U.S. market access.

Find out more about the latest corporate developments and financial reports at the Intelligent Bio Solutions investor portal.